Bioworld Consulting Laboratories LLC (BCL)

Bioworld Consulting Laboratories, LLC (BCL) designs, develops, manufactures and markets monoclonal antibodies, antigens and new methods for detection and identification of viral infectious agents.

BCL has a complete and innovative range of technologies, enabling the company to take advantage of growth in the most dynamic market segments:

* Monoclonal antibodies -- company developed a rapid immunization and hybridoma development method which allows delivery of custom made monoclonal antibodies in 6 to10 weeks.
* Rapid Immunoassays -- detection and measurement of infectious agents and pathology markers based on an antigen/antibody reaction using newly developed rapid and sensitive assays. Generally these assays are done in 10-20 minutes compared to traditional assays which may take several hours to complete. In most cases the sensitivity is two to eight fold better than the corresponding traditional method.
* Molecular biology -- a new technology is under development, which allows detection of a single copy of DNA or RNA in situ in less than one hour. Estimated release of the kit using the new method for detection of EBV, HHV-6 and HHV-7 is December 2009.

ELISA,

human monoclonal antibody development
mouse monoclonal antibody developement
monoclonal antibodies
ELISA kits
virology